Efficacy Study of Cardizem in Pulmonary Arterial Hypertension

• Status: Withdrawn
• Trial end date: 2014-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if cardizem is effective in the treatment of nitric oxide non-responder pulmonary arterial hypertension.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of South Florida
• Treatments: Calcium Channel Blockers; Diltiazem

Criteria

Inclusion Criteria:

• Adult participants

• Confirmed WHO class I pulmonary arterial hypertension

• Nitric Oxide Non-Responders on right heart catheterization

• Experience dyspnea, NYHA III-IV with poor oxygenation and quality of life despite standard treatments

• Must be able to swallow medications

Exclusion Criteria:

• Pulmonary hypertension secondary to 1) elevations in pulmonary venous pressures (i.e. left heart disease), 2) chronic hypoxemic states from lung diseases such as COPD, sleep-disordered breathing, alveolar hypoventilation disorders, chronic exposure to high altitude and developmental abnormalities 3) chronic thromboembolic disease, 4) sarcoidosis, 5) Lymphangiomyomatosis, 5) Pulmonary Langerhans Cell Histiocytosis

• Already on a calcium channel blocker

• Systolic blood pressure less than 90

• Heart rate less than 55

• Pregnant

• Cannot sign informed consent

• Right heart failure

• Pulmonary Veno-occlusive disease